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Parameter
Symplicity HTN 2
RDN group (n=52)
Luebeck RDN Registry
(N =79)
Age in years 58 + 12 63 + 11
Body Mass Index 31+5 29 + 6
Diabetes (%) 40 33
No. of antihypertensive
drugs
5.2 + 1.5 5.5 + 1.6
SBP @ baseline in mmHg 178 + 18 174 + 24
DBP @ Baseline in mmHg 97 + 16 92 + 15
HR @ baseline in 1/min 74 69 + 11
SBP @ 6 mths F/U in
mmHg
- 32 + 7 - 23 + 9
DBP @ 6 mths F/U in
mmHg
- 12 +3 -9 + 4
HR @ 6 mth F/U in 1/min 69 64 + 10
SBP @ 12 mths F/U in
mmHg
- 28 + 7 - 20 + 8
DBP @ 12 mths F/U in
mmHg
-10 + 4 -9 + 5
HR @ 12 mths F/U in 1/
min
68 62 + 11
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SBackground: The PARADISE system (ReCor Medical, Menlo Park, CA) is a unique
therapeutic non-focused ultrasound system designed to perform renal denervation
while preventing circumferential damage to the renal artery for resistant hypertension.
The system allows for targeted delivery of ultrasound energy with thermal injury at
depths beyond 0.5 mm while cooling and preserving tissue in its immediate vicinity. A
preclinical porcine animal study was conducted to evaluate the safety and effective-
ness of this technology.
Methods: Renal denervation was performed bilaterally using the PARADISE system
in healthy Yorkshire cross swine (n¼9). Animals were either survived for 7 days, or
sacriﬁced acutely. For the acute study, a standard denervation protocol was used
distally within each renal artery, and for comparison, the same treatment without
cooling was delivered proximally. The arteries were removed, ﬂushed, and stained
with triphenyltetrazolium chloride (TTC) to assess for medial damage. At 7 days,
whole kidney norepinephrine levels were obtained (HPLC-MS) to assess damage to
sympathetic nerves, and histopathologic assessment (H&E) of the renal arteries was
performed to evaluate the integrity of the endothelium, media, and adventitia and
nerve damage was assessed in the perirenal space.
Results: TTC staining of the renal arteries demonstrated non-viable tissue in the
locations where energy was applied without cooling, while standard denervation
treatment with cooling demonstrated preservation of the media. H&E staining
demonstrated minimal to no injury to the endothelium and media at 7 days. Extensive
periadventitial damage was observed with up to 80% nerves damaged within
susceptible zones. Kidney norepinephrine levels were signiﬁcantly reduced in all
animals and correlated with the degree of nerve damage.
Conclusions: The Paradise ultrasound system effectively ablated the sympathetic
nerves surrounding the renal arteries while preserving the media thus demonstrating
the importance of cooling.
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Background: Catheter-based renal artery denervation therapy has become established
as a therapeutic option in patients with resistant hypertension. We have previously
presented safety and efﬁcacy using the ﬁrst generation multi-electrode renal dener-
vation system with the EnligHTN catheter (St. Jude Medical). The next generation
system utilises a novel algorithm for the delivery of 1 minute of radiofrequency
energy, optimised for simultaneous delivery of therapy through all electrodes, with an
interactive generator interface. This study will evaluate the safety and performance of
the next generation EnligHTN Renal Denervation System in patients with drug-
resistant, uncontrolled hypertension.
Methods: Inclusion criteria include patients 18-80 years of age with a systolic BP
160 mmHg and an average daytime systolic ambulatory BP135 mmHg on three or
more antihypertensive agents (including a diuretic). The primary end-points are 1) to
characterize the rate of serious procedural and device related adverse events through 6
months and 2) the change in ofﬁce BP at 6 months. The secondary end-points include
the changes in 24 hour ABP and the characterization of renovascular safety and renal
function change over time. The multi-electrode RF catheter will be introduced in
a renal artery, and RF energy will be delivered simultaneously for 60 seconds across
all 4 electrodes. Next, the catheter will be withdrawn slightly and rotated, and the
denervation sequence will be repeated. This process will then be repeated on the
contralateral renal artery. A minimum of 30 patients will be included in the trial.
Results: To date 10 patients from three sites (63.4  6.4 years, 7M/3F) have been
included. Baseline BP 178.515.2/97.314.0 mmHg, ABPM 159.420.1/87.39.6.
Eight denervations were successfully performed in each artery for all patients. Median
ablation procedure time was 19 min. No vascular or renal artery complications were
observed.
Conclusions: Accumulated results from all sites will be presented at the meeting.
Initial experience suggests that the SJM next generation EnligHTN System may
shorten procedure times while still delivering a safe, predictable and reproducible
denervation pattern.
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Background: In arterial hypertension risk factor evaluation, including LV mass
measurements and risk stratiﬁcation using risk different charts and scores is usual
practice. In chronic heart failure NT-proBNP has been shown to be a marker of wall
stress and prognosis. Renal denervation (RDN) is a therapeutic strategy for patientsB152 JACC Vol 62/18/Suppl B j Octobwith resistant arterial hypertension. The changes of NT-proBNP in patients under-
going RDN have never been described.
Methods: We investigated 33 patients with resistant hypertension (18 male, 15
female). Inclusion criteria at baseline were a systolic BP 160 mmHg (150 mmHg
in diabetics), treated with 3 antihypertensive drugs, an estimated glomerular ﬁltra-
tion rate 45 mL/min/1.73m2 and suitable renovascular anatomy. Medication was
unchanged during the follow-up period. All patients underwent bilateral RDN.
Systolic (SBP) and diastolic blood (DBP) pressures were measured at baseline and at
the 6 months follow-up with an automated OMRON device. Plasma at baseline and
after 6 months was analyzed for NT-proBNP using the commercially available
Elecsys proBNP sandwich immunoassay on an Elecsys 2010 (Roche Diagnostics,
Mannheim).
Results: (all results are given in meanSEM). Mean age was 63  6 years. Ofﬁce
SBP and DBP were reduced by 20.2  2.5 and 5.8 1.6 mmHg (p<0.01)
after 6 months. Mean NT-proBNP was reduced from 173.4 pg/ml at baseline to
163.4 pg/ml after 6 months (p 0.25) Decrease of systolic blood pressure (SBP)
signiﬁcantly correlates with reduction of NT-proBNP (p 0.01). There was no
signiﬁcant correlation between diastolic blood pressure decrease and NT-proBNP
reduction.
Conclusions: (i) Six months after RDN patients with resistant hypertension experi-
enced a substantial reduction in SBP and DBP. (ii) Systolic blood pressure decrease
correlates with NT-pro-BNP reduction as suggestive marker of reduced LV stress after
successful RDN and signiﬁcant SBP reduction.
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Background: Resistant hypertension is associated with substantially increased risk for
cardiovascular events and mortality. The growing prevalence of hypertension
worldwide (1.6 billion predicted by 2025) combined with an aging population high-
lights the need for effective blood pressure (BP) lowering therapies for patients of all
ages. First data from randomized clinical studies suggest a marked reduction in
systolic (SBP) and diastolic (DBP) 6 month after the procedure. However, there are
limited data out side from clinical trials.
Methods: Data from “real world” patients enrolled in a local RDN program (inclusion
criteria according to Symplicity HTN-2) who completed 12 months follow-up are
compared to data of a controlled clinical trial. All patients had resistant hypertension
deﬁned as a systolic BP (SBP) 160 mm Hg (>150 mmHg in diabetics) while on 3
antihypertensive medications including a diuretic. Demographic data and change from
baseline BP and HR was assessed for each subset at 6 and 12 month.
Results: Table 1Conclusions: The results suggest that RDN performed in a clinical setting has equal
blood pressure lowering effects as when performed in RCT. Furthermore, reduction of
ofﬁce BP and ofﬁce heart rate after renal denervation is consistent under real world
conditions.er 27–November 1, 2013 j TCT Abstracts/POSTER/Renal Denervation
